Compound as highly selective ROS1 inhibitor and use thereof
Disclosed are a class of compounds having a highly selective inhibition of ROS1, and the use thereof in the preparation of drugs for treating diseases related to abnormal ROS1 kinase expression. Specifically disclosed are compounds represented by formula (IV) and a pharmaceutically acceptable salt thereof.
1 . A compound represented by formula (IV) or a pharmaceutically acceptable salt thereof,
wherein,
R 1 is selected from H, F, Cl, Br, I, OH, NH 2 , CN and C 1-3 alkyl optionally substituted with 1, 2 or 3 R a ;
R 2 is selected from H and C 1-3 alkyl optionally substituted with 1, 2 or 3 R b ;
L 1 is selected from —C 1-3 alkyl-, —C 3-6 cycloalkyl- and —C 3-6 cycloalkyl-C 1-3 alkyl-, and the —C 1-3 alkyl-, —C 3-6 cycloalkyl- and —C 3-6 cycloalkyl-C 1-3 alkyl- are optionally substituted with 1, 2 or 3 R c ;
L 2 is selected from —C 1-3 alkyl-and-O—;
R a , R b and R c are each independently selected from F, Cl, Br and CH 3 .
2 . The compound or the pharmaceutically acceptable salt thereof according to claim 1 , wherein R 1 is selected from H, F, Cl, Br, I, OH, NH 2 , CN and CH 3 , and the CH 3 is optionally substituted with 1, 2 or 3 R a .
3 . The compound or the pharmaceutically acceptable salt thereof according to claim 2 , wherein R 1 is F.
4 . The compound or the pharmaceutically acceptable salt thereof according to claim 1 , wherein R 2 is selected from H and CH 3 .
5 . The compound or the pharmaceutically acceptable salt thereof according to claim 1 , wherein L 1 is selected from —CH 2 —, —CH(CH 3 )CH 2 —, -cyclopropyl-CH 2 — and -cyclobutyl-, and the —CH 2 —, —CH(CH 3 )CH 2 —, -cyclopropyl-CH 2 — and -cyclobutyl- are optionally substituted with 1, 2 or 3 R c .
6 . The compound or the pharmaceutically acceptable salt thereof according to claim 5 , wherein L 1 is selected from —CH 2 —, —CH(CH 3 )CH 2 —,
7 . The compound or the pharmaceutically acceptable salt thereof according to claim 1 , wherein L 2 is selected from —CH 2 — and —O—.
8 . The compound or the pharmaceutically acceptable salt thereof according to claim 1 , wherein the structural unit
is selected from
9 . The compound or the pharmaceutically acceptable salt thereof according to claim 1 , wherein the structural unit
is selected from
10 . The compound or the pharmaceutically acceptable salt thereof according to claim 1 , wherein the compound is selected from:
11 . A compound represented by the following formula or a pharmaceutically acceptable salt thereof, wherein the compound is selected from:
12 . The compound or the pharmaceutically acceptable salt thereof according to claim 11 , wherein the compound is selected from:
13 . A compound represented by formula (V) or formula (VI),
wherein,
R 1 is selected from H, F, Cl, Br, I, OH, NH 2 , CN and C 1-3 alkyl optionally substituted with 1, 2 or 3 R a ;
R 2 is selected from H and C 1-3 alkyl optionally substituted with 1, 2 or 3 R b ;
R 3 is selected from OH and O—C 1-3 alkyl;
L 1 is selected from —C 1-3 alkyl-, —C 3-6 cycloalkyl- and —C 3-6 cycloalkyl-C 1-3 alkyl-, and the —C 1-3 alkyl-, —C 3-6 cycloalkyl- and —C 3-6 cycloalkyl-C 1-3 alkyl- are optionally substituted with 1, 2 or 3 R c ;
R a , R b and R c are each independently selected from F, Cl, Br and CH 3 .
14 . A preparation method of the compound according to claim 1 , wherein the method comprises the following reaction routes:
or preparing the compound represented by formula (VI) from the compound represented by formula (V) under the condition of alkali and solvent A, and then preparing the compound represented by formula (IV) from the compound represented by formula (VI) under the condition of ligand and solvent B;
wherein,
R 1 is selected from H, F, Cl, Br, I, OH, NH 2 , CN and C 1-3 alkyl optionally substituted with 1, 2 or 3 R a ;
R 2 is selected from H and C 1-3 alkyl optionally substituted with 1, 2 or 3 R b ;
R 3 is selected from OH and O—C 1-3 alkyl;
L 1 is selected from —C 1-3 alkyl-, —C 3-6 cycloalkyl- and —C 3-6 cycloalkyl-C 1-3 alkyl-, and the —C 1-3 alkyl-, —C 3-6 cycloalkyl- and —C 3-6 cycloalkyl-C 1-3 alkyl- are optionally substituted with 1, 2 or 3 R c ;
R a , R b and R c are each independently selected from F, Cl, Br and CH 3 ;
the alkali is selected from lithium hydroxide, sodium hydroxide, potassium hydroxide, lithium carbonate, sodium carbonate, potassium carbonate, calcium carbonate, magnesium carbonate, lithium bicarbonate, sodium bicarbonate, potassium bicarbonate, calcium bicarbonate, magnesium bicarbonate, sodium formate, potassium propionate, trimethylamine, triethylamine, pyridine, 4-dimethylaminopyridine and N-ethyldiisopropylamine;
the solvent A is selected from N,N-dimethylformamide, acetonitrile, dichloromethane, dimethyl sulfoxide, N-methylpyrrolidone and N,N-dimethylacetamide;
the ligand is selected from triphenylphosphine, trimethylphenylphosphine, tricyclohexylphosphine, tri-tert-butylphosphine, tributylphosphine and diethylphenylphosphine;
the solvent B is selected from toluene, xylene, ethylene glycol dimethyl ether, dioxane, tetrahydrofuran, N,N-dimethylformamide, dimethyl sulfoxide and N-methylpyrrolidone.
15 . A method for inhibiting ROS1 in a subject in need thereof, comprising administering the compound or the pharmaceutically acceptable salt thereof according to claim 1 to the subject.
16 . A method for treating cancer in a subject in need thereof, comprising administering the compound or the pharmaceutically acceptable salt thereof according to claim 1 to the subject.
17 . A method for treating lung cancer in a subject in need thereof, comprising administering the compound or the pharmaceutically acceptable salt thereof according to claim 1 to the subject.
18 . The compound or the pharmaceutically acceptable salt thereof according to claim 1 , wherein the compound is:
19 . The compound or the pharmaceutically acceptable salt thereof according to claim 1 , wherein the compound is:
20 . The compound or the pharmaceutically acceptable salt thereof according to claim 1 , wherein the compound is: